Belgium· BE-AMP-SAM361261-00
Lamivudine Teva Pharma B.V. 300 mg
A lamivudine product containing lamivudine, registered in Belgium by Teva. The same ATC class is registered in 17 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lamivudine is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AF05 (lamivudine), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Lamivudine · ATC J05AF05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lamivudine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $2.42 in France to $7.71 in Switzerland — a ×3.2 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lamivudine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.71
- IT Italy$6.75
- FR France$2.42
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lamivudine
- Manufacturer
- Teva
- Country
- Belgium (BE)
- ATC code
- J05AF05
- ATC class
- Lamivudine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
207 interactions on record for lamivudine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine · interactions on record
207 records
- 6 severe
- 36 moderate
- 165 info
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lamivudine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEPIVIRViiV Healthcare BV, Amersfoort
- United StatesEPIVIRViiV Healthcare Company
- SpainEPIVIR 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- NetherlandsEpivir 300 mg, omhulde tablettenViiV healthcare B.V.
- FranceEPIVIR 300 mg, comprimé pelliculéVIIV HEALTHCARE UK (ROYAUME-UNI)
- FinlandEpivirViiV Healthcare BV
- IrelandEpivir 300 mg film-coated tabletsViiV Healthcare BV
- Switzerland3TC
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · Lamivudin Sandoz
- Cyprus · Lamivudine Normon
- Germany · Lamivudin Aurobindo, Lamivudin Mylan
- Spain · Lamivudina Accord, Lamivudina Aurovitas
- France · Lamivudine Arrow, Lamivudine Sandoz
- United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
- Iceland · Epivir, Lamivudine Teva
- Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
- Liechtenstein · Epivir, Lamivudine Teva
- Netherlands · Lamivudine Accord, Lamivudine Aurobindo
- Norway · Epivir, Lamivudine Teva
- Poland · Lamivudine Aurovitas
- Portugal · Lamivudina Aurobindo, Lamivudina Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f948a897-b021-4e83-a0ee-761a50627a80 GET /v1/drugs/f948a897-b021-4e83-a0ee-761a50627a80?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Lamivudine Teva Pharma B.V. 300 mg",
"name_fr": "Lamivudine Teva Pharma B.V. 300 mg",
"name_nl": "Lamivudine Teva Pharma B.V. 300 mg",
"amp_code": "SAM361261-00",
"strengths": [
"300.0000",
"300.0000"
],
"pack_count": 9,
"substances": [
"Lamivudine",
"Sodium Starch Glycolate (Type A)",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lamivudine",
"authorisation_numbers": [
"EU/1/09/596/008",
"EU/1/09/596/009",
"EU/1/09/596/010",
"EU/1/09/596/011",
"EU/1/09/596/012",
"EU/1/09/596/013",
"EU/1/09/596/014",
"EU/1/09/596/018",
"EU/1/09/596/016"
]
}See everything about lamivudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.